Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'

Cramer highlighted Smithfield Foods as “very inexpensive,” citing record Q2 adjusted operating profit of $300M and first-half record of $638M (+2% YoY), implying an ~8x earnings valuation and a 5.6% yield. He was more mixed elsewhere: BillionToOne shares fell 3.9% after mixed results, while Eton Pharmaceuticals dipped 0.7% but guided FY26 revenue above estimates. On deal news, IES Holdings rose 5.8% after agreeing to acquire DBM Global for ~$650M (cash + stock), while Babcock & Wilcox dropped 3.8% as it continues to “lose so much money.”

Analysis

The most actionable read-through is the spread between cash-generative, low-growth consumer names and capital-intensive roll-up / project names. SFD can look inexpensive for months, but that multiple is only durable if hog/feed spreads stay benign and trade promotion does not re-ignite; otherwise the yield becomes a value trap as earnings mean-revert. Any improvement there also pressures TSN/HRL to defend shelf space, so the trade is really about category pricing power, not one stock.

BW’s top line is less important than whether incremental revenue converts into free cash flow. In equipment and project businesses, the first good quarter often reflects timing, while leverage and working-capital drag show up later; that makes BW vulnerable to a 1-3 quarter fade if margins or backlog quality soften. By contrast, IESC/DBMG is a better event-driven setup: the market usually gives credit for scale immediately, then re-rates on financing terms, dilution, and integration discipline after close.

In small-cap healthcare, ETON is the cleaner quality-vs-valuation long over the next 1-3 months, while BLLN looks more like a good company with a less obvious catalyst path. The consensus mistake is assuming any validation of a growth story keeps the stock moving; with these names, the next quarter’s sell-through and margin cadence matter more than the headline print. QXO remains a capital-allocation story: upside exists if acquisition cadence and operating execution compound, but the multiple compresses quickly if growth is just financial engineering.

Key Decisions for Investors

• Long SFD / short TSN for 1-3 months as a relative-value trade on meat margin durability; exit if SFD guides to lower spreads or commodity input costs re-accelerate.
• Fade BW on strength via a 2-4 month put spread or outright short; thesis breaks only if free cash flow turns sustainably positive and EBITDA margins expand for two consecutive quarters.
• Pair long IESC / short DBMG into the deal close; own the acquirer for operating leverage, but reduce if funding terms imply dilution or if integration commentary turns cautious.
• Long ETON vs short BLLN on a 1-2 quarter horizon; prefer the cleaner guide-up story, and cover if BLLN reaccelerates sales without margin giveback.
• Small starter long QXO on pullbacks only; make it a watchlist position until capital deployment and operating KPIs prove the roll-up is more than optionality.